TCGX Acquisition Corp. and TriGemX Bio, Inc. confidentially submitted a draft registration statement on Form S-4 to the SEC for their proposed business combination. The draft includes a preliminary proxy statement and prospectus; after the registration statement is publicly filed and declared effective, TCGX will mail definitive materials to shareholders as of a record date to be established.
The combination is expected to close in the first quarter of 2027, subject to required approvals, SEC effectiveness and other customary closing conditions. The proposed combined company would be listed on Nasdaq under the ticker TGEM.
TCGX Acquisition Corp. reported that proposed business-combination partner TriGemX Bio, Inc. shared a LinkedIn post on October 19, 2026. TCGX intends to file a Form S-4 registration statement with proxy materials for TCGX shareholders and a prospectus relating to securities to be issued to TriGemX stockholders if the combination is completed. The proposed transaction will be submitted to TCGX shareholders for consideration.
After the registration statement is filed and declared effective, TCGX will mail definitive voting materials to TCGX shareholders and TriGemX stockholders as of a record date to be established. Completion is not assured on the terms currently contemplated. The communication lists possible risks including failure to obtain approvals, meet Nasdaq listing standards, secure financing, or achieve product-development milestones.
TCGX Acquisition Corp. disclosed a proposed business combination with TriGemX Bio, Inc. that values TriGemX at about $600 million. The transaction is slated to close in the first quarter of 2027 and will be submitted to TCGX shareholders for consideration. TCGX intends to file a Form S-4 registration statement with proxy materials, and the announcement states there can be no assurance the combination will be completed.
TriGemX is described as having $246 million in cash to work with, mostly from a $160 million investment by existing backers and other healthcare investors. It has begun a 1,500-person Phase 3 trial of elismetrep for acute migraine and plans to finish a migraine-prevention trial and prepare for U.S. commercialization. The announcement says the financing should support the acute trial and a potential FDA submission.
TCGX Acquisition Corp. agreed to combine with TriGemX Bio, Inc., with closing expected in the first quarter of 2027, subject to shareholder approvals and other conditions. At closing, PIPE investors would buy 16,000,000 shares of New TriGemX common stock at $10.00 per share for $160 million in gross proceeds, subject to subscription conditions. Assuming no TCGX public-shareholder redemptions, total gross proceeds are expected to be approximately $246 million, including approximately $86 million from TCGX’s trust; expected post-transaction equity value is approximately $600 million.
TriGemX stockholders would exchange their shares for New TriGemX stock and roll 100% of their equity, without cash proceeds; TCGX Class A shareholders may redeem shares for their pro rata portion of trust funds. TriGemX’s agreed pre-money equity value is $361 million; the exchange ratio is based on that value, a $10.00 per-share New TriGemX value and TriGemX’s fully diluted share count. TriGemX’s obligation to close also requires at least $150 million in Available Closing Cash. TriGemX stated that approximately $111 million in cash as of October 1, 2026, funds operations into Q3 2027. Before the merger, TCGX is to domesticate in Delaware and change its name to TriGemX Bio, Inc.
TCGX Acquisition Corp. (TCGX), a Cayman Islands blank check company, reported its first results for the period from May 26, 2026 (inception) through June 30, 2026, focused on formation and IPO preparation with no operating revenues and a net loss of $67,614 from formation, general and administrative costs. At June 30, 2026 the company had total assets of $253,176, all in prepaid expenses and deferred offering costs, against current liabilities of $295,790 and a working capital deficit of $288,997, funded primarily by a $43,395 related-party promissory note and sponsor-paid expenses.
Subsequent to quarter end, TCGX completed its IPO on August 6, 2026, selling 8,625,000 Class A shares at $10.00 for $86,250,000 of gross proceeds and a concurrent private placement of 522,500 shares for $5,225,000. $86,250,000 was deposited into a Trust Account, with total transaction costs of $5,837,054. The company also entered into a $20,000,000 forward purchase agreement and has a 24‑month “Completion Window” after the IPO closing to complete a business combination, with standard SPAC shareholder redemption rights tied to the Trust Account balance.
TCGX Acquisition Corp. (TCGX) is reported to have 500,000 Class A ordinary shares held by RA Capital Healthcare Fund, L.P., representing 5.5% of the Class A shares. This ownership percentage is based on 9,147,500 Class A ordinary shares outstanding as of August 6, 2026.
RA Capital Management, L.P. serves as investment adviser to the Fund and has been delegated the sole power to vote and dispose of the Fund’s TCGX shares. RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners for Section 13(d) purposes but each disclaims beneficial ownership other than for determining reporting obligations.
TCGX Acquisition Corp. (TCGX), a Cayman Islands blank check company focused on healthcare (especially life sciences and medtech, including potential targets in China), is conducting an IPO of 7,500,000 Class A ordinary shares at $10.00 per share, for $75,000,000 in gross proceeds. The underwriters have a 45‑day option to buy up to 1,125,000 additional shares.
$75,000,000 (or $86,250,000 with the over‑allotment) plus private placement proceeds will be placed in a U.S. trust account at $10.00 per share. Public holders can redeem in connection with the initial business combination or certain extensions, generally at trust value per share, but any holder (together with affiliates and group members) is limited to redeeming more than 15% of IPO shares without consent. If no business combination is completed within 24 months (subject to shareholder‑approved extensions), TCGX will liquidate and redeem public shares.
The sponsor and underwriters will buy 500,000 private placement shares at $10.00 (up to 522,500 with over‑allotment), and the sponsor and insiders already hold 2,156,250 Class B founder shares bought for $25,000, designed to represent 20% of post‑IPO shares (excluding private placement). Founder shares convert into Class A on at least a one‑for‑one basis with anti‑dilution protection, creating potential material dilution for public investors. A forward purchase agreement with Fund III commits a minimum of 2,000,000 additional Class A shares at $10.00 at business‑combination closing, subject to Fund III investment committee approval.